Clinical perspectives on head lice treatment.

Thought leaders from around the country provide their views on the latest evidence-based clinical data regarding head lice therapy and management.

 

Dr. J. Marshall Clark: Professor, Veterinary & Animal Sciences and Director, Massachusetts Pesticide Analysis Laboratory at the Veterinary & Animal Sciences Department, University of Massachusetts, Amherst.

 

Dr. Christopher Belcher: President, Infectious Disease of Indiana and Director of Pediatric Infectious Diseases, Peyton Manning Children’s Hospital.

 

Dr. Shirley Gordon: Professor at Florida Atlantic University, Christine E. Lynn College of Nursing; Director, Head Lice Treatment and Prevention Project.

NAT-RRW3-000

Indication
Natroba™ Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Natroba™ Topical Suspension should be used in the context of an overall lice management program:

Important Safety Information

Indication
Natroba™ Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Natroba™ Topical Suspension should be used in the context of an overall lice management program:
• Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
• Wash personal care items such as combs, brushes, and hair clips in hot water
• A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

Important Safety Information
Natroba™ Topical Suspension contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants when administered intravenously. Most common adverse events were: application site redness (3%), eye redness (2%) and application site irritation (1%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.